|
1
|
Jemal A, Murray T, Samuels A, Ghafoor A,
Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin.
53:5–26. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taichman RS, Loberg RD, Mehra R and Pienta
KJ: The evolving biology and treatment of prostate cancer. J Clin
Invest. 117:2351–2361. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Norgaard M, Jensen AØ, Jacobsen JB, Cetin
K, Fryzek JP and Sørensen HT: Skeletal related events, bone
metastasis and survival of prostate cancer: A population based
cohort study in Denmark (1999 to 2007). J Urol. 184:162–167. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheung WM, Hui WS, Chu PW, Chiu SW and Ip
NY: Ganoderma extract activates MAP kinases and induces the
neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS
Lett. 486:291–296. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS,
Shiao MS and Ho CK: The anti-tumor effect of Ganoderma lucidum is
mediated by cytokines released from activated macrophages and T
lymphocytes. Int J Cancer. 70:699–705. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wasser SP and Weis AL: Therapeutic effects
of substances occurring in higher Basidiomycetes mushrooms: a
modern perspective. Crit Rev Immunol. 19:65–96. 1999.PubMed/NCBI
|
|
7
|
Ji Z, Tang Q, Zhang J, Yang Y, Jia W and
Pan Y: Immunomodulation of RAW264.7 macrophages by GLIS, a
proteopolysaccharide from Ganoderma lucidum. J Ethnopharmacol.
112:445–450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizushina Y, Takahashi N, Hanashima L,
Koshino H, Esumi Y, Uzawa J, Sugawara F and Sakaguchi K: Lucidenic
acid O and lactone, new terpene inhibitors of eukaryotic DNA
polymerases from a basidiomycete, Ganoderma lucidum. Bioorg Med
Chem. 7:2047–2052. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferreira IC, Heleno SA, Reis FS, Stojkovic
D, Queiroz MJ, Vasconcelos MH and Sokovic M: Chemical features of
Ganoderma polysaccharides with antioxidant, antitumor and
antimicrobial activities. Phytochemistry. 114:38–55. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lakshmi B, Ajith TA, Sheena N, Gunapalan N
and Janardhanan KK: Antiperoxidative, anti-inflammatory and
antimutagenic activities of ethanol extract of the mycelium of
Ganoderma lucidum occurring in South India. Teratog Carcinog
Mutagen. Suppl 1:S85–S97. 2003. View Article : Google Scholar
|
|
11
|
Lin ZB and Zhang HN: Anti-tumor and
immunoregulatory activities of Ganoderma lucidum and its possible
mechanisms. Acta Pharmacol Sin. 25:1387–1395. 2004.PubMed/NCBI
|
|
12
|
Pan K, Jiang Q, Liu G, Miao X and Zhong D:
Optimization extraction of Ganoderma lucidum polysaccharides and
its immunity and antioxidant activities. Int J Biol Macromol.
55:301–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao W, Jiang X, Deng W, Lai Y, Wu M and
Zhang Z: Antioxidant activities of Ganoderma lucidum
polysaccharides and their role on DNA damage in mice induced by
cobalt-60 gamma-irradiation. Food Chem Toxicol. 50:303–309. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Min BS, Gao JJ, Nakamura N and Hattori M:
Triterpenes from the spores of Ganoderma lucidum and their
cytotoxicity against meth-A and LLC tumor cells. Chem Pharm Bull
(Tokyo). 48:1026–1033. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stanley G, Harvey K, Slivova V, Jiang J
and Sliva D: Ganoderma lucidum suppresses angiogenesis through the
inhibition of secretion of VEGF and TGF-beta1 from prostate cancer
cells. Biochem Biophys Res Commun. 330:46–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang J, Slivova V, Valachovicova T,
Harvey K and Sliva D: Ganoderma lucidum inhibits proliferation and
induces apoptosis in human prostate cancer cells PC-3. Int J Oncol.
24:1093–1099. 2004.PubMed/NCBI
|
|
17
|
Qi M, Liu Z, Shen C, Wang L, Zeng J, Wang
C, Li C, Fu W, Sun Y and Han B: Overexpression of ETV4 is
associated with poor prognosis in prostate cancer: Involvement of
uPA/uPAR and MMPs. Tumour Biol. 36:3565–3572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sehgal I, Forbes K and Webb MA: Reduced
secretion of MMPs, plasminogen activators and TIMPS from prostate
cancer cells derived by repeated metastasis. Anticancer Res.
23:39–42. 2003.PubMed/NCBI
|
|
19
|
Shiao MS: Natural products of the
medicinal fungus Ganoderma lucidum: Occurrence, biological
activities, and pharmacological functions. Chem Rec. 3:172–180.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu W, Wang H, Pang X, Yao W and Gao X:
Characterization and antioxidant activity of two
low-molecular-weight polysaccharides purified from the fruiting
bodies of Ganoderma lucidum. Int J Biol Macromol. 46:451–457. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bao X, Liu C, Fang J and Li X: Structural
and immunological studies of a major polysaccharide from spores of
Ganoderma lucidum (Fr.) Karst. Carbohydr Res. 332:67–74. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao QZ and Lin ZB: Ganoderma lucidum
polysaccharides peptide inhibits the growth of vascular endothelial
cell and the induction of VEGF in human lung cancer cell. Life Sci.
78:1457–1463. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wachtel-Galor S, Choi SW and Benzie IF:
Effect of Ganoderma lucidum on human DNA is dose dependent and
mediated by hydrogen peroxide. Redox Rep. 10:145–149. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mau JL, Lin HC and Chen CC: Antioxidant
properties of several medicinal mushrooms. J Agric Food Chem.
50:6072–6077. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Yuan JP, Chung CK and Chen XJ:
Antitumor activity of the sporoderm-broken germinating spores of
Ganoderma lucidum. Cancer Lett. 182:155–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ruan W, Wei Y and Popovich DG: Distinct
responses of cytotoxic ganoderma lucidum triterpenoids in human
carcinoma cells. Phytother Res. 29:1744–1752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li P, Deng YP, Wei XX and Xu JH:
Triterpenoids from Ganoderma lucidum and their cytotoxic
activities. Nat Prod Res. 27:17–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng CR, Yue QX, Wu ZY, Song XY, Tao SJ,
Wu XH, Xu PP, Liu X, Guan SH and Guo DA: Cytotoxic triterpenoids
from Ganoderma lucidum. Phytochemistry. 71:1579–1585. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El Dine RS, El Halawany AM, Ma CM and
Hattori M: Anti-HIV-1 protease activity of lanostane triterpenes
from the vietnamese mushroom Ganoderma colossum. J Nat Prod.
71:1022–1026. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Min BS, Nakamura N, Miyashiro H, Bae KW
and Hattori M: Triterpenes from the spores of Ganoderma lucidum and
their inhibitory activity against HIV-1 protease. Chem Pharm Bull
(Tokyo). 46:1607–1612. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang XQ, Ip FC, Zhang DM, Chen LX, Zhang
W, Li YL, Ip NY and Ye WC: Triterpenoids with neurotrophic activity
from Ganoderma lucidum. Nat Prod Res. 25:1607–1613. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee I, Seo J, Kim J, Kim H, Youn U, Lee J,
Jung H, Na M, Hattori M, Min B and Bae K: Lanostane triterpenes
from the fruiting bodies of Ganoderma lucidum and their inhibitory
effects on adipocyte differentiation in 3T3-L1 Cells. J Nat Prod.
73:172–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wilasrusmee C, Kittur S, Siddiqui J, Bruch
D, Wilasrusmee S and Kittur DS: In vitro immunomodulatory effects
of ten commonly used herbs on murine lymphocytes. J Altern
Complement Med. 8:467–475. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goldar S, Khaniani MS, Derakhshan SM and
Baradaran B: Molecular mechanisms of apoptosis and roles in cancer
development and treatment. Asian Pac J Cancer Prev. 16:2129–2144.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lopez J and Tait SW: Mitochondrial
apoptosis: Killing cancer using the enemy within. Br J Cancer.
112:957–962. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen D, Peng F, Cui QC, Daniel KG, Orlu S,
Liu J and Dou QP: Inhibition of prostate cancer cellular proteasome
activity by a pyrrolidine dithiocarbamate-copper complex is
associated with suppression of proliferation and induction of
apoptosis. Front Biosci. 10:2932–2939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang Y, Kaul S, Zhang D, Anantharam V and
Kanthasamy AG: Suppression of caspase-3-dependent proteolytic
activation of protein kinase C delta by small interfering RNA
prevents MPP+-induced dopaminergic degeneration. Mol Cell Neurosci.
25:406–421. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dickens LS, Powley IR, Hughes MA and
MacFarlane M: The ‘complexities’ of life and death: Death receptor
signalling platforms. Exp Cell Res. 318:1269–1277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tait SW and Green DR: Mitochondria and
cell death: Outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vogler M, Walter HS and Dyer MJS:
Targeting anti-apoptotic BCL2 family proteins in haematological
malignancies-from pathogenesis to treatment. Br J Haematol.
178:364–379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ibrado AM, Huang Y, Fang G, Liu L and
Bhalla K: Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced
CPP32/Yama protease activity and apoptosis of human acute
myelogenous leukemia HL-60 cells. Cancer Res. 56:4743–4748.
1996.PubMed/NCBI
|
|
43
|
Lebedeva I, Rando R, Ojwang J, Cossum P
and Stein CA: Bcl-xL in prostate cancer cells: Effects of
overexpression and down-regulation on chemosensitivity. Cancer Res.
60:6052–6060. 2000.PubMed/NCBI
|
